190 related articles for article (PubMed ID: 37509310)
1. A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer.
Ploeg EM; Britsch I; van Wijngaarden AP; Ke X; Hendriks MAJM; Samplonius DF; Helfrich W
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509310
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
Ploeg EM; Samplonius DF; Xiong X; Ke X; Hendriks MAJM; Britsch I; van Wijngaarden AP; Zhang H; Helfrich W
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734877
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.
Ploeg EM; Ke X; Britsch I; Hendriks MAJM; Van der Zant FA; Kruijff S; Samplonius DF; Zhang H; Helfrich W
Cancer Lett; 2021 Aug; 521():109-118. PubMed ID: 34464670
[TBL] [Abstract][Full Text] [Related]
4. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.
Gammelgaard OL; Terp MG; Renn C; Labrijn AF; Hamaker O; Nielsen AY; Vever H; Hansen SW; Gjerstorff MF; Müller CE; Parren PW; Ditzel HJ
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096528
[TBL] [Abstract][Full Text] [Related]
5. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
Koopmans I; Hendriks D; Samplonius DF; van Ginkel RJ; Heskamp S; Wierstra PJ; Bremer E; Helfrich W
Oncoimmunology; 2018; 7(8):e1466016. PubMed ID: 30221065
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
8. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
[TBL] [Abstract][Full Text] [Related]
9. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway.
Wurm M; Schaaf O; Reutner K; Ganesan R; Mostböck S; Pelster C; Böttcher J; de Andrade Pereira B; Taubert C; Alt I; Serna G; Auguste A; Stadermann KB; Delic D; Han F; Capdevila J; Nuciforo PG; Kroe-Barrett R; Adam PJ; Vogt AB; Hofmann I
Mol Cancer Ther; 2021 Nov; 20(11):2250-2261. PubMed ID: 34482286
[TBL] [Abstract][Full Text] [Related]
10. The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.
Da M; Chen L; Enk A; Ring S; Mahnke K
Front Immunol; 2022; 13():914799. PubMed ID: 35711418
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
12. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
[TBL] [Abstract][Full Text] [Related]
13. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
15. EpCAM
Wang L; Dorn P; Simillion C; Froment L; Berezowska S; Tschanz SA; Haenni B; Blank F; Wotzkow C; Peng RW; Marti TM; Bode PK; Moehrlen U; Schmid RA; Hall SRR
Am J Physiol Lung Cell Mol Physiol; 2020 Nov; 319(5):L794-L809. PubMed ID: 32726135
[TBL] [Abstract][Full Text] [Related]
16. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
18. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
[TBL] [Abstract][Full Text] [Related]
19. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
Häusler SF; Del Barrio IM; Diessner J; Stein RG; Strohschein J; Hönig A; Dietl J; Wischhusen J
Am J Transl Res; 2014; 6(2):129-39. PubMed ID: 24489992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
